An interventional study of Peer Mentorship in Heart Failure, Mentorship and Peer Support, sponsored by Samantha Anthony. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Samantha Anthony · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Heart Failure with a site in Canada — 77 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Canada.
Among the 454 studies in Heart Failure with a site in Canada, this one is the 255th largest by planned enrollment of the 362 interventional ones that give a count, is one of 12 that started in 2026, is one of 162 with no phase, reaches primary completion later than 63 of the 98 other live ones, and was the 439th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →77 of the 454 studies in Heart Failure with a site in Canada are open now. Recruiting first, the newest first:
AnaCardio AB · Sites in Canada, United States, Bulgaria and 5 more countries
Ages 18–85
AstraZeneca · Sites in Canada, United States, Argentina and 29 more countries
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Bayer · Sites in Canada, United States, Argentina and 20 more countries
Ages up to 18
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 72 · Phase 3 106 · Phase 4 24
First in 1983; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 226 across the 362 interventional studies, 360 across the 91 observational. Of the 307 that completed or were terminated, 127 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
201 of 454 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Samantha Anthony as lead sponsor.
Samantha Anthony has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
29 of the studies in Heart Failure with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05873881Phase 3Hamilton Health Sciences CorporationCOLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease | 2027-06 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 29 to your calendar (.ics) → With an account.
Among the 454 studies in Heart Failure with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Young adults with heart failure, including those who have undergone a heart transplant, experience considerable psychosocial stressors associated with living with a chronic illness, including heightened levels of anxiety and depression, and poor health-related quality of life compared to 'healthy' peers. Psychosocial challenges during young adulthood are especially concerning as this life stage represents a unique transitional period for fostering self-identity, friendships, mastery, and decision-making competencies. As young people with heart failure transition into adult healthcare systems, they take on greater personal responsibility due to their increasing independence and involvement in care decisions, and require more support and resources to live longer, healthier lives. Peer support provided by a person with a similar experience has been found to improve disease self-management and psychosocial health outcomes in pediatric healthcare.
An established, online mentorship program, iPeer2Peer (iP2P), will be employed through a pilot feasibility waitlist randomized controlled trial with repeated measures across five sites. Sixty mentees will be recruited and randomized into intervention and control groups. Thirty mentees in the intervention group will be matched 1:1 with 20 trained mentors. These pairings will connect over 12 weeks through video calls and text messaging to provide peer support to improve self-management and psychosocial health outcomes.
Primary Objective: to evaluate the feasibility of the iP2P program in terms of participant: (a) recruitment and withdrawal rates, (b) adherence with the program, (c) perceptions regarding the acceptability and level of engagement in the iP2P program, and (d) perceptions of barriers and enablers of the iP2P program.
Secondary Objective: to explore the iP2P program's impact on preliminary psychosocial outcomes in:
i.Mentees- (a) disease self-management, (b) perceived social support, (c) emotional distress, (d) resiliency and (e) hope; ii.Mentors- (a) perceived social role satisfaction, (b) emotional distress, and (c) hope.
A waitlist pilot RCT allows for an effective comparison of the study intervention with a control group receiving standard of care while not disadvantaging the control group who will have the option of participating in the intervention following the completion of the trial.
Up to 80 participants will be enrolled in this study at five sites: Mazankowski Alberta Heart Institute (Edmonton), St. Boniface Hospital (Winnipeg), Toronto General Hospital (Toronto), the University of British Columbia Division of Cardiology - Vancouver General Hospital and St Paul's Hospital (Vancouver).
We expect 20 adult mentors and 60 young adult mentees will be enrolled across these sites, with 4-6 mentors and about 10-15 mentees per site. The mentees will be randomized to the experimental (iP2P program; n=30) or control (waitlist; n=30) group. Mentees assigned to the waitlist will receive the iP2P program once all outcome measures are complete.
All mentees will be asked to participate in semi-structured individual interviews at baseline (ME T1) and and all mentees in the intervention group will be asked to participate in semi-structured interviews at 12 weeks - immediately post-intervention (ME T2). Interviews will be conducted by an interviewer trained in qualitative methods by telephone, in-person or virtually via the PHIPA-compliant version of Zoom or Microsoft Teams (depending on participants' preference), at a time that is convenient for the participant. Interviews will be guided by a semi-structured interview guide. ME T1 interviews will aim to assess motivations for participation, hopes and expectations, and preferences around mentor characteristics; and ME T2 interviews will aim to assess the primary outcomes evaluating feasibility.
All mentors will be asked to participate in a focus group/semi-structured interview prior to mentor training (MR T1) and study end (MR T2). MR T1 focus groups/interviews will aim to assess motivations for participation and hopes and expectations, and MR T2 focus groups/interviews will aim to assess the primary outcomes evaluating feasibility. Focus groups/interviews will be conducted by an interviewer trained in qualitative methods. Focus groups/interviews will be conducted on a mutually agreed upon date and over the internet via a web-based video communication program (e.g., PHIPA-compliant version of Zoom or Microsoft Teams).
The semi-structured individual interviews and focus groups will be audiotaped, transcribed and analyzed using qualitative descriptive approach using thematic and content analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Heart disease patients include:
Exclusion Criteria:
In addition to their standard medical care, mentees in the experimental group will receive mentorship and support via the iP2P program. Trained mentors will provide information and support to mentee participants to encourage participation in self-management skill-building tailored to their needs. Each mentor will work with no more than two mentees at once for the study. Efforts will be made to pair mentors and mentees who share similar characteristics (e.g., similar disease severity, symptom profile, treatment regimen experiences, caregiver role, sex/gender, geographic area of residence). To ensure safety, a member of the research team will monitor all calls and messaging conversations as well as intervene in any potential safety concerns (e.g., discussion of suicidal ideation) or inappropriate behavior (e.g. bullying).
Behavioral: Peer Mentorship
The control group will receive standard care without the iP2P intervention. The control group will be offered the iP2P intervention after completion of all outcome measures for a period of 12 weeks with the same research team support.
The iPeer2Peer intervention is a peer support mentorship program that will provide modelling and reinforcement by pre-screened and trained peer mentors to the mentees. The mentorship program will encourage mentees to develop and engage in self-management and transition skills and support the participants; practice of these skills. The mentors will provide information and support to mentee participants via 5-10 calls (using WhatsApp) of 20-30 minute durations and text messaging (using WhatsApp) for 12 weeks to encourage participation in self-management skill building tailored to their needs.
Also known as: Peer mentoring, Peer support
Recruitment and withdrawal rates
(a) Recruitment rates (more than 70%) and withdrawal rates (less than 15%) as calculated using data recorded in participant recruitment log.
Time frame: Baseline to study completion
Level of engagement
Measured via semi-structured interviews or focus groups.
Time frame: 12 weeks
Adherence
More than 80% rate of completion of at least five audio or video calls over 12 weeks and 100% rate of completion of all online outcome measures as calculated using data recorded in participant program tracking log.
Time frame: 12 weeks
Acceptability
When the innovation is agreeable, palatable or satisfactory. Measured via focus groups or semi-structued interviews.
Time frame: 12 weeks
Barriers and enablers
Measured via semi-structued interviews or focus groups.
Time frame: 12 weeks
Perceived social role satisfaction (Mentors)
Measured by the PROMIS Satisfaction with Social Roles and Activities
Time frame: Baseline to study completion, an average of 1 year
Emotional distress (Mentors)
Measured by the General Anxiety Disorder-7 and the Patient Health Questionnaire Depression Scale
Time frame: Baseline to study completion, an average of 1 year
Hope (Mentors)
Measured by the Adult Hope Scale
Time frame: Baseline to study completion, an average of 1 year
Disease self-management (Mentees)
Measured by the Partners in Health Scale
Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion
Percevied social support (Mentees)
Measured by the Multidimensional Scale of Perceived Social Support
Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion
Emotional distress (Mentees)
Measured by the General Anxiety Disorder-7 and the Patient Health Questionnaire Depression Scale
Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion
Resiliency (Mentees)
Measured by the Brief Resilience Scale
Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion
Hope (Mentees)
Measured by the Adult Hope Scale
Time frame: Baseline to 12 weeks post-program completion and 24 weeks post-program completion
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 14 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2026, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.